Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DIAGNOSTIC_TEST: Whole Genome Sequencing|DIAGNOSTIC_TEST: RNA-Sequencing|DIAGNOSTIC_TEST: Microbiome analysis|DIAGNOSTIC_TEST: ctDNA analysis|DIAGNOSTIC_TEST: TCR-β repertoire sequencing|DIAGNOSTIC_TEST: PBMCs phenotyping|DRUG: Pembrolizumab|DRUG: Chemotherapy
Sponsor: Vall d'Hebron Institute of Oncology